Building out in obesity

AstraZeneca is quietly assembling an obesity portfolio that could give it a credible path to challenge the entrenched leaders in the space, while adding a new leg of growth beyond 2030.

AstraZeneca plc (LSE:AZN; NYSE:AZN) is no stranger to GLP-1s, having marketed Bydureon exenatide, the world’s first once-weekly GLP-1R agonist for Type II diabetes...